These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 29709013

  • 21. Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors.
    Chisati EM, Constantinou D, Lampiao F.
    PLoS One; 2020; 15(1):e0227893. PubMed ID: 31935270
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
    Bloch M, Tong WW, Hoy J, Baker D, Lee FJ, Richardson R, Carr A, TROP (Switch from Tenofovir to Raltegravir for Low Bone Density) study team.
    HIV Med; 2014 Jul; 15(6):373-80. PubMed ID: 24460797
    [Abstract] [Full Text] [Related]

  • 25. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT.
    HIV Clin Trials; 2015 Jul; 16(2):66-71. PubMed ID: 25872972
    [Abstract] [Full Text] [Related]

  • 26. The association of bone mineral density with HIV infection and antiretroviral treatment in women.
    Anastos K, Lu D, Shi O, Mulligan K, Tien PC, Freeman R, Cohen MH, Justman J, Hessol NA.
    Antivir Ther; 2007 Jul; 12(7):1049-58. PubMed ID: 18018763
    [Abstract] [Full Text] [Related]

  • 27. Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy.
    Xu Z, He P, Xian J, Lu W, Shu J, Luo W, Gan C, Ke R, Xia J, Han Z, Huang M.
    Curr HIV Res; 2021 Jul; 19(1):40-46. PubMed ID: 32940183
    [Abstract] [Full Text] [Related]

  • 28. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
    Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, di Gregorio S, Puig J, Gómez G, Clotet B, Negredo E, Osteoporosis Study Group.
    AIDS; 2010 Nov 27; 24(18):2827-33. PubMed ID: 21045635
    [Abstract] [Full Text] [Related]

  • 29. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients.
    Casado JL, Santiuste C, Vazquez M, Bañón S, Rosillo M, Gomez A, Perez-Elías MJ, Caballero C, Rey JM, Moreno S.
    AIDS; 2016 Jun 01; 30(9):1423-31. PubMed ID: 26919733
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.
    Hamzah L, Samarawickrama A, Campbell L, Pope M, Burling K, Fisher M, Gilleece Y, Walker-Bone K, Post FA.
    AIDS; 2015 Sep 10; 29(14):1785-1792. PubMed ID: 26372384
    [Abstract] [Full Text] [Related]

  • 33. Adverse bone health and abnormal bone turnover among perinatally HIV-infected Asian adolescents with virological suppression.
    Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Prasitsuebsai W, Sophonphan J, Sohn AH, Ananworanich J, Puthanakit T, Bone-D Study Group.
    HIV Med; 2017 Apr 10; 18(4):235-244. PubMed ID: 27477214
    [Abstract] [Full Text] [Related]

  • 34. Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
    Calza L, Magistrelli E, Colangeli V, Borderi M, Conti M, Mancini R, Viale P.
    Antivir Ther; 2016 Apr 10; 21(3):217-24. PubMed ID: 26405177
    [Abstract] [Full Text] [Related]

  • 35. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
    Couffignal C, Kolta S, Flamant M, Cazanave C, Haymann JP, Mentré F, Duval X, Leport C, Raffi F, APROCO-COPILOTE ANRS CO8 Study Group.
    AIDS Res Hum Retroviruses; 2020 May 10; 36(5):399-405. PubMed ID: 31891665
    [Abstract] [Full Text] [Related]

  • 36. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
    Negredo E, Domingo P, Pérez-Álvarez N, Gutiérrez M, Mateo G, Puig J, Escrig R, Echeverría P, Bonjoch A, Clotet B.
    J Antimicrob Chemother; 2014 Dec 10; 69(12):3368-71. PubMed ID: 25125679
    [Abstract] [Full Text] [Related]

  • 37. Prevalence and risk factors for bone mineral density changes in antiretroviral therapy-naive human immunodeficiency virus-infected adults: a Chinese cohort study.
    Zeng YQ, Xiao J, Li CL, Wang Y, Zhang L, Pang XL, Wang D, Du J, Zhao HX.
    Chin Med J (Engl); 2020 Dec 03; 133(24):2940-2946. PubMed ID: 33278100
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P.
    AIDS; 2009 Jul 17; 23(11):1367-76. PubMed ID: 19424051
    [Abstract] [Full Text] [Related]

  • 40. Bone mineral density in HIV-infected women taking antiretroviral therapy: a systematic review.
    Carvalho EH, Gelenske T, Bandeira F, Albuquerque Mda F.
    Arq Bras Endocrinol Metabol; 2010 Mar 17; 54(2):133-42. PubMed ID: 20485901
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.